Short Interest in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Declines By 42.4%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totalling 2,700,000 shares, a decrease of 42.4% from the June 30th total of 4,690,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the days-to-cover ratio is presently 2.2 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on MRNS shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Truist Financial reissued a “buy” rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Marinus Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $13.79.

Marinus Pharmaceuticals Trading Up 1.1 %

Shares of MRNS traded up $0.01 during trading hours on Friday, reaching $1.43. The stock had a trading volume of 174,678 shares, compared to its average volume of 1,314,470. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $11.26. The firm has a 50-day moving average of $1.38 and a 200 day moving average of $5.25. The company has a market cap of $78.55 million, a P/E ratio of -0.54 and a beta of 1.12.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, meeting analysts’ consensus estimates of ($0.68). The business had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. On average, sell-side analysts expect that Marinus Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $34,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Marinus Pharmaceuticals by 383.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 5,003 shares during the last quarter. Values First Advisors Inc. boosted its stake in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Marinus Pharmaceuticals during the 1st quarter worth about $384,000. Finally, Trexquant Investment LP acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth about $553,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.